Oncolytic Treatment and Cure of Neuroblastoma by a Novel Attenuated Poliovirus in a Novel Poliovirus-Susceptible Animal Model
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (6) , 2857-2864
- https://doi.org/10.1158/0008-5472.can-06-3713
Abstract
Neuroblastoma is one of the most common solid tumors in children. Treatment is of limited utility for high-risk neuroblastoma and prognosis is poor. Resistance of neuroblastoma to conventional therapies has prompted us to search for a novel therapeutic approach based on genetically modified polioviruses. Poliovirus targets motor neurons leading to irreversible paralysis. Neurovirulence can be attenuated by point mutations or by exchange of genetic elements between different picornaviruses. We have developed a novel and stable attenuated poliovirus, replicating in neuroblastoma cells, by engineering an indigenous replication element (cre), copied from a genome-internal site, into the 5′-nontranslated genomic region (mono-crePV). An additional host range mutation (A133G) conferred replication in mouse neuroblastoma cells (Neuro-2aCD155) expressing CD155, the poliovirus receptor. Crossing immunocompetent transgenic mice susceptible to poliovirus (CD155 tg mice) with A/J mice generated CD155 tgA/J mice, which we immunized against poliovirus. Neuro-2aCD155 cells were then transplanted into these animals, leading to lethal tumors. Despite preexisting high titers of anti-poliovirus antibodies, established lethal s.c. Neuro-2aCD155 tumors in CD155 tgA/J mice were eliminated by intratumoral administrations of A133Gmono-crePV. No signs of paralysis were observed. Interestingly, no tumor growth was observed in mice cured of neuroblastoma that were reinoculated s.c. with Neuro-2aCD155. This result indicates that the destruction of neuroblastoma cells by A133Gmono-crePV may lead to a robust antitumor immune response. We suggest that our novel attenuated oncolytic poliovirus is a promising candidate for effective oncolytic treatment of human neuroblastoma or other cancer even in the presence of present or induced antipolio immunity. [Cancer Res 2007;67(6):2857–64]Keywords
This publication has 35 references indexed in Scilit:
- Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.Clinical Cancer Research, 2006
- Oncolytic Virotherapy: Approaches to Tumor Targeting and Enhancing Antitumor EffectsSeminars in Oncology, 2005
- To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational controlOncogene, 2005
- Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental eventVirus Research, 2005
- Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic ActivityJournal of Virology, 2003
- Recruitment of Nectin-3 to Cell-Cell Junctions through trans-Heterophilic Interaction with CD155, a Vitronectin and Poliovirus Receptor That Localizes to αvβ3 Integrin-containing Membrane MicrodomainsJournal of Biological Chemistry, 2003
- Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5Journal of Clinical Investigation, 2002
- Virally Induced Lytic Cell Death Elicits the Release of Immunogenic GRP94/gp96Journal of Biological Chemistry, 2001
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- The Promoters for Human and Monkey Poliovirus ReceptorsPublished by Elsevier ,1997